Hot Features
Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
GSK PLC 19 November 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Dr Hal Barron b) Position/status...
GSK PLC on Tuesday said that its investigational targeted inhibitor linerixibat demonstrated sound results for a trea ...
GSK PLC 19 November 2024 Issued: 19 November 2024, London UK Linerixibat shows positive Phase III results in cholestatic pruritus (relentless itch) in primary biliary cholangitis (PBC...
GSK PLC on Thursday said its Blenrep drug has shown overall survival benefits in patients with relapsed or refractory ...
GSK PLC 14 November 2024 Issued: 14 November 2024, London UK Blenrep shows overall survival benefit in head-to-head DREAMM-7 phase III trial for relapsed/refractory multiple myeloma · ...
GSK PLC 13 November 2024 BLOCK LISTING SIX MONTHLY RETURN Date: 13 November 2024 Name of applicant: GSK plc Name of scheme: GlaxoSmithKline plc 2017 Deferred Annual Bonus Plan...
GSK PLC 12 November 2024 GSK plc (the 'Company') Transaction notification 1. Details of PDMR/person closely associated with them ('PCA') a) Name Emma Walmsley b) Position/status Chief...
GSK PLC 11 November 2024 GSK plc GSK publishes provisional dividend dates GSK announces the following dividend dates for 2025: These dates are indicative and may be subject to...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -47 | -3.47247875877 | 1353.5 | 1364.5 | 1282.5 | 12275192 | 1310.61943585 | DE |
| 4 | -151 | -10.3602058319 | 1457.5 | 1462.5 | 1282.5 | 10283630 | 1375.12499315 | DE |
| 12 | -356 | -21.4135338346 | 1662.5 | 1678 | 1282.5 | 8420977 | 1477.38240893 | DE |
| 26 | -463.5 | -26.186440678 | 1770 | 1808.5 | 1282.5 | 8000386 | 1536.01672936 | DE |
| 52 | -94.9 | -6.77179962894 | 1401.4 | 1820 | 1282.5 | 7834790 | 1568.61907528 | DE |
| 156 | -221.5 | -14.4960732984 | 1528 | 1824.4 | 1282.5 | 8658976 | 1532.92443754 | DE |
| 260 | -403.1 | -23.5786148807 | 1709.6 | 1857 | 1190.8 | 8846945 | 1513.76675056 | DE |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
